Today, Kintara Therapeutics, Inc. (NASDAQ:KTRA), a pharmaceutical company specializing in the development of cancer treatments, announced that it has distributed a letter to certain stockholders regarding an upcoming Special Meeting of Stockholders. The meeting is part of the process to complete the proposed merger with TuHURA Biosciences, Inc., which was previously announced.
The merger, which is subject to stockholder approval, is set to combine Kintara's cancer treatment development efforts with TuHURA's resources. The companies believe that the merger will advance their shared goal of developing innovative therapies for patients.
The letter to stockholders, which is included as an exhibit in the 8-K filing with the Securities and Exchange Commission (SEC), provides details about the Special Meeting. However, the contents of the letter have not been filed for purposes of the SEC’s liability provisions and are not incorporated by reference into any SEC filings.
Kintara has already filed a Registration Statement on Form S-4, which includes a definitive proxy statement and a final prospectus. The registration statement was declared effective on August 13, 2024, and the definitive proxy statement/prospectus has been sent to Kintara’s stockholders to solicit their votes regarding the proposed merger.
Investors and security holders are encouraged to read the registration statement, the proxy statement/prospectus, and any other relevant documents filed with the SEC, as they contain important information about the merger.
The communication from Kintara also contains forward-looking statements regarding expectations for the merger's completion and its potential benefits. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.
The proposed merger is not guaranteed and is contingent upon various conditions, including the approval of Kintara's stockholders. The Special Meeting is a crucial step in this process, and the outcome will determine the future direction of the combined company's efforts in cancer treatment research and development. The information in this article is based on a press release statement from Kintara Therapeutics, Inc.
In other recent news, TuHURA Biosciences has been making strides in cancer treatment, securing exclusive rights to an advanced immunotherapy asset, KVA12123, currently in clinical trials. The company has also reported positive results from a Phase 1b trial of its leading cancer vaccine candidate, IFx-2.0, conducted with Kintara Therapeutics.
In other corporate developments, Kintara Therapeutics held its Annual Meeting of Stockholders, where four directors were elected, and the company's executive officers' compensation was approved. The appointment of Marcum LLP as Kintara's independent registered public accounting firm for the fiscal year ending June 30, 2024, was also ratified. These are the recent developments for Kintara Therapeutics and TuHURA Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.